Cep-11981 clinical trials
Also written ESK981 and CEP-11981.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses cep-11981 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
University of Michigan Rogel Cancer Center (2) · Barbara Ann Karmanos Cancer Institute (2) · Cephalon (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses cep-11981 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingPhase 2University of Michigan Rogel Cancer CenterNCT05988918Written as ESK981
- ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerTerminatedPhase 2Barbara Ann Karmanos Cancer InstituteNCT04159896Written as Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
- Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaTerminatedPhase 2University of Michigan Rogel Cancer CenterNCT03562507Written as ESK981
- ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate CancerCompletedPhase 2Barbara Ann Karmanos Cancer InstituteNCT03456804Written as ESK981
- Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced CancerCompletedPhase 1CephalonNCT00875264Written as CEP-11981 (kinase inhibitor)
Codes
What other systems call cep-11981 · ClinicalTrials.gg INT006024
- UNII (FDA) J8AY0Z4CBPCEP-11981Confirmed FDA, Wikidata
- Wikidata Q27075849cep-11981Confirmed FDA, Wikidata
- NCI Thesaurus C82379Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | J8AY0Z4CBP | CEP-11981 | Confirmed FDA, Wikidata |
| Wikidata | Q27075849 | cep-11981 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C82379 | Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.